Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statistical analysis of disease onset during lifespan with left truncation.

Biometrics·2026
Same author

Regression for Left-Truncated and Right-Censored Data: A Semiparametric Sieve Likelihood Approach.

Statistics in medicine·2026
Same author

Nonparametric estimation of conditional survival function with time-varying covariates using DeepONet.

Lifetime data analysis·2026
Same author

Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern®.

Ophthalmology·2026
Same author

Pulmonary artery sarcoma with mediastinal metastasis: a case report.

Frontiers in oncology·2026
Same author

Clinical Manifestations.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

Value of 10-2 Visual Field Testing for Detecting Progression in Patients with Glaucoma.

Ophthalmology·2026
Same journal

Comparative Five-Year Risks of Systemic Complications with Biologic versus Conventional Therapy in Non-infectious Uveitis.

Ophthalmology·2026
Same journal

Diverse Conjunctival Adverse Events Associated with Tisotumab Vedotin.

Ophthalmology·2026
Same journal

The Answer Is Blowing in the Wind: Uncovering Hidden Glaucoma Risk Factors.

Ophthalmology·2026
Same journal

Nonsteroidal Anti-inflammatory Drug Use Reduces the Risk of Age-Related Macular Degeneration in Electronic Health Record Analysis: Signal or Solution?

Ophthalmology·2026
Same journal

Metastasis of Nasopharyngeal Squamous Cell Carcinoma to the Angle.

Ophthalmology·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

The relationship between statin use and open-angle glaucoma.

Joshua D Stein1, Paula Anne Newman-Casey, Nidhi Talwar

  • 1Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA. jdstein@med.umich.edu

Ophthalmology
|June 26, 2012
PubMed
Summary
This summary is machine-generated.

Statins significantly reduce the risk of developing open-angle glaucoma (OAG) in individuals with hyperlipidemia. Continuous statin use for two years lowered OAG risk by 8%, suggesting a protective effect.

Related Experiment Videos

Last Updated: May 21, 2026

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

Area of Science:

  • Ophthalmology
  • Cardiology
  • Pharmacology

Background:

  • Hyperlipidemia is a common condition associated with cardiovascular disease.
  • Open-angle glaucoma (OAG) is a leading cause of irreversible blindness.
  • The potential neuroprotective effects of statins are an area of ongoing research.

Purpose of the Study:

  • To investigate the association between the use of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and the risk of developing open-angle glaucoma (OAG).
  • To assess the impact of statin therapy on the progression of glaucoma and the need for interventions in patients with hyperlipidemia.

Main Methods:

  • Retrospective, longitudinal cohort analysis of individuals aged 60 years or older with hyperlipidemia.
  • Utilized data from a national US managed care network (2001-2009).
  • Multivariable Cox regression analyses adjusted for sociodemographic factors and comorbidities to evaluate the relationship between statin use and OAG development, progression, and treatment needs.

Main Results:

  • A 0.3% decreased hazard of developing OAG for every additional month of statin consumption.
  • Continuous statin use for two years was associated with an 8% reduced risk of OAG.
  • Statin use also decreased the hazard of progressing from glaucoma suspect to OAG by 0.4% per month of exposure, with a 9% reduction for two years of continuous use.
  • A 0.4% decreased hazard of requiring medical treatment for OAG per month of statin exposure was observed; no difference in surgical intervention needs was found.

Conclusions:

  • Statin use is linked to a significant reduction in the risk of developing open-angle glaucoma in individuals with hyperlipidemia.
  • The findings support existing evidence from basic science and observational studies on the protective role of statins against OAG.
  • Further interventional prospective studies are warranted to confirm the role of statins in preventing early-stage OAG.